Vascular Calcification
Conditions
Keywords
coronary calcification, vascular calcification, active vitamin D, alfacalcidol
Brief summary
Active vitamin D at therapeutic dose may prevent vascular calcification but in supraphysiologic dose may precipitate it.
Detailed description
Active vitamin D compound is used frequently in the treatment of hyperparathyroidism in chronic kidney disease. Recent evidence from animal studies suggested that low dose of active vitamin D may be protective against vascular calcification, whereas high dose could precipitate it. The present study will examine the effect of low dose oral alfacalcidol on coronary artery calcification in predialysis chronic kidney disease patients with hyperparathyroidism.
Interventions
DRUGoral alfacalcidol
Oral alfacalcidol 0.5 microgram per day
DRUGno drug
no drug
Sponsors
Ramathibodi Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Predialysis chronic kidney disease with GFR \< 90 mL/min/1.73m2 * PTH above the upper limit of normal * serum calcium and phosphate below the upper limit of normal
Exclusion criteria
* changes in GFR\>15% during the past 3 months * receive elemental calcium\>500 mg/day * currently taking active vitamin D, oral calcium with elemental calcium\>500 mg/day or bisphosphonate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Coronary Artery Calcification | 6 months and 12 months |
Countries
Thailand
Contacts
Primary ContactSinee Disthabanchong, MD
Outcome results
None listed